

AMENDMENT

This Amendment, effective as of the last date of signature below constitutes a valid and enforceable Amendment to the Sponsorship Agreement signed on 8 Oct 2024 related to research, production, distribution and communication of the whitepaper in relation to Cancer Plan V (the "Agreement") between Gilead Sciences Denmark APS, Gammel Kongevej 60, 1850 Frederiksberg C, Denmark ("Gilead") and LyLe, Patientforeningen for Lymfekaræft, leukæmi og MDS, organization number: CVR 31 30 98 33, (Gilead and LyLe collectively referred to as "Parties").

WHEREAS, the Parties have entered into the Agreement;

WHEREAS, the Parties now wish to extend the Agreement; and

WHEREAS, the Parties wish that all other terms and conditions of the Agreement shall remain unchanged and shall be retained in full force and effect.

NOW, THEREFORE, the Parties hereto agree as follows:

1. Capitalized terms not expressly defined herein shall have the meaning set forth in the Agreement.
2. The Parties agree to the extension of the Agreement on the same terms and conditions, other than as amended herein, which shall now expire on 31 Dec 2025 unless extended further by mutual agreement of both parties in writing.
3. Unless otherwise expressly agreed herein, all terms and conditions of the Agreement shall remain unchanged and shall be retained in full force and effect.
4. Gilead hereby agrees to provide LyLe the sum of DKK 8.500 for the purpose of supporting advocacy work based on the Whitepaper developed by the LyLe in relation to Cancer Plan V. The financial support is provided based on LyLe's application and budget for additional support related to the Whitepaper, Exhibit 1.
5. In return for the provision of the financial support LyLe has acknowledged the sponsorship by mentioning Gilead as a sponsor in Whitepaper ('hvidbog'), incl. Gilead logo.

IN WITNESS WHEREOF, the Parties, through their authorized representatives, have executed two (2) identical copies of this Amendment.

PATIENTFORENIGNEN FOR LYMFEKRÆFT, LEUKÆMI OG MDS (LYLE)

Date: 28 marts 2025

DocuSigned by:

Rita O. Christensen

F92DBD4EBA834E6...

Name: Rita O. Christensen

Title: Chair, Patientforeningen LyLe

Gilead Sciences Denmark APS

Date: 28 marts 2025

Signed by:

Hans Lynggaard Jørgensen

DC29D702F649407...

Name: Hans Lynggaard Jørgensen

Title: Associate Director,
Government Affairs Lead, Cell Therapy
European Mid-Size Markets & Nordics